K
42.26
0.43 (1.03%)
| Previous Close | 41.83 |
| Open | 41.83 |
| Volume | 222,300 |
| Avg. Volume (3M) | 501,298 |
| Market Cap | 3,203,128,576 |
| Price / Earnings (TTM) | 93.91 |
| Price / Earnings (Forward) | 31.25 |
| Price / Sales | 5.41 |
| Price / Book | 5.97 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Mixed | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.38 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Median | 50.00 (18.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 13 Jan 2026 | 50.00 (18.32%) | Buy | 38.60 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Kiniksa Pharmaceuticals Provides Corporate Update |
| 07 Jan 2026 | Announcement | Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 12 Nov 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |